HomeMLLCF • OTCMKTS
add
Molecular Partners AG
Nakaraang pagsara
$6.52
Sakop ng taon
$3.40 - $10.14
Market cap
245.02M USD
Average na Volume
53.00
P/E ratio
-
Dividend yield
-
Primary exchange
SWX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (CHF) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 2.74M | -10.23% |
Gastos sa pagpapatakbo | 4.49M | -17.47% |
Net na kita | -11.32M | 23.37% |
Net profit margin | -413.62 | 14.63% |
Kita sa bawat share | — | — |
EBITDA | -15.25M | -5.35% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (CHF) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 174.13M | -25.06% |
Kabuuang asset | 185.60M | -24.10% |
Kabuuang sagutin | 17.06M | -23.74% |
Kabuuang equity | 168.54M | — |
Natitirang share | 32.87M | — |
Presyo para makapag-book | 1.27 | — |
Return on assets | -20.65% | — |
Return on capital | -22.53% | — |
Cash Flow
Net change in cash
| (CHF) | Mar 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -11.32M | 23.37% |
Cash mula sa mga operasyon | -17.05M | -3.05% |
Cash mula sa pag-invest | 17.61M | 422.58% |
Cash mula sa financing | -300.00K | -1.01% |
Net change in cash | 1.04M | 107.39% |
Malayang cash flow | -11.21M | -30.15% |
Tungkol
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Itinatag
2004
Website
Mga Empleyado
168
